Next-generation sequencing (NGS)-based genetic testing, which provides abundant genetic information about cancer, has developed therapeutic strategies against driver mutations such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1), for NSCLC (11). The gene discussed is ALK; the disease is cancer.